Skip to main content
Premium Trial:

Request an Annual Quote

Roche Posts Flat MDx Sales for First Nine Months of 2014

NEW YORK (GenomeWeb) – Roche today reported that its molecular diagnostics sales were flat year over year for the first nine months of 2014.

The Swiss pharmaceuticals, diagnostics, and research products firm posted overall sales of CHF 34.78 billion ($36.79 billion) for the nine-month period ended Sept. 30, down slightly from sales of CHF 34.87. At constant exchange rates, its sales were up 5 percent, the firm said.

Sales for Roche's Diagnostics Division were up around 1 percent at CHF 7.79 billion compared to CHF 7.68 billion for the first nine months of 2013. At constant exchange rates, its diagnostics revenue was up 6 percent year over year.

Roche reported molecular diagnostics sales of CHF 1.17 billion, flat with CHF 1.19 billion for the first nine months of 2013, but up 5 percent at constant exchange rates. Excluding its genome sequencing products sales, Roche said that its underlying MDx sales increased 7 percent, driven by tests for viral infections, blood screening, and the cobas HPV test. It also noted 8 percent growth for its nucleic acid purification/real-time PCR reagents.

Sales for the firm's professional diagnostics products increased 3 percent to CHF 4.40 billion, while diabetes care sales were up 3 percent at CHF 1.72 billion, and its tissue diagnostics business saw growth of 6 percent year over year to CHF 509 million.

Revenue for its Pharmaceuticals Division decreased 1 percent year over year to CHF 26.97 billion from CHF 27.19 billion.

Roche confirmed its FY 2014 outlook for low- to mid-single digit sales growth at constant exchange rates.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more